Phase II clinical trial - Sein Adjuvant

BREASTIMMUNE03 / CA209-9XD
Sein Adjuvant
Ouvert depuis le: 07.09.2020
Site: Paris
Ouvert depuis le: 11.12.2019
Site: Saint-Cloud
Public cible
Adulte
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (BreastImmune03)
Description de l'essai

To evaluate the clinical benefit of a post-operative adjuvant therapy combining radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitabine in Triple Negative Breast Cancer (TNBC) patients with residual disease after neoadjuvant chemotherapy